Tower Research Capital LLC (Trc) Gamida Cell Ltd. Transaction History

Tower Research Capital LLC (Trc)

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$1.15 - $2.1 $15,123 - $27,617	13,151 Added 209.88%	19,417 $25,000
Q3 2022 Nov 10, 2022	SELL	$1.53 - $3.39 $14,057 - $31,147	-9,188 Reduced 59.45%	6,266 $10,000
Q2 2022 Aug 15, 2022	BUY	$1.73 - $4.29 $19,175 - $47,550	11,084 Added 253.64%	15,454 $27,000
Q1 2022 May 12, 2022	SELL	$2.22 - $4.47 $8,644 - $17,406	-3,894 Reduced 47.12%	4,370 $18,000
Q4 2021 Feb 14, 2022	BUY	$2.2 - $4.46 $8,797 - $17,835	3,999 Added 93.76%	8,264 $21,000
Q3 2021 Nov 15, 2021	SELL	$3.85 - $6.44 $2,648 - $4,430	-688 Reduced 13.89%	4,265 $17,000
Q2 2021 Aug 16, 2021	BUY	$5.85 - $8.33 $11,331 - $16,135	1,937 Added 64.22%	4,953 $32,000
Q1 2021 May 17, 2021	BUY	$7.8 - $12.43 $20,623 - $32,864	2,644 Added 710.75%	3,016 $25,000
Q4 2020 Feb 16, 2021	SELL	$4.07 - $11.0 $36,906 - $99,748	-9,068 Reduced 96.06%	372 $3,000
Q3 2020 Nov 16, 2020	BUY	$3.93 - $4.59 $37,099 - $43,329	9,440 New	9,440 $39,000
Q1 2020 May 15, 2020	SELL	$2.9 - $4.76 $4,042 - $6,635	-1,394 Closed	0 $0
Q4 2019 Feb 07, 2020	BUY	$4.01 - $5.25 $2,947 - $3,858	735 Added 111.53%	1,394 $6,000
Q3 2019 Nov 05, 2019	SELL	$3.0 - $5.09 $654 - $1,109	-218 Reduced 24.86%	659 $3,000
Q2 2019 Aug 13, 2019	BUY	$4.98 - $11.32 $4,367 - $9,927	877 New	877 $4,000

Ticker GMDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,319,600
Market Cap $2.29M
Description
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials ...

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.